EAM Investors LLC Makes New $3.98 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

EAM Investors LLC acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 71,815 shares of the company's stock, valued at approximately $3,976,000. EAM Investors LLC owned about 0.19% of Tarsus Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Summit Investment Advisors Inc. lifted its position in Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after buying an additional 244 shares during the period. Crowley Wealth Management Inc. purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $25,000. Bank of New York Mellon Corp grew its holdings in Tarsus Pharmaceuticals by 0.5% in the fourth quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock valued at $5,644,000 after purchasing an additional 498 shares during the period. Swiss National Bank increased its position in Tarsus Pharmaceuticals by 1.2% during the fourth quarter. Swiss National Bank now owns 52,333 shares of the company's stock worth $2,898,000 after purchasing an additional 600 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Tarsus Pharmaceuticals by 10.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company's stock worth $449,000 after purchasing an additional 789 shares during the period. Institutional investors and hedge funds own 90.01% of the company's stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction on Monday, March 24th. The stock was sold at an average price of $50.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer now directly owns 824,106 shares of the company's stock, valued at approximately $41,205,300. This trade represents a 0.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dianne C. Whitfield sold 2,315 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $107,161.35. Following the completion of the transaction, the insider now owns 50,751 shares of the company's stock, valued at $2,349,263.79. This trade represents a 4.36 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock worth $1,581,173 over the last ninety days. Company insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Stock Down 0.8 %

NASDAQ:TARS traded down $0.39 on Monday, reaching $48.86. The stock had a trading volume of 191,542 shares, compared to its average volume of 681,333. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28. The stock has a market cap of $1.88 billion, a P/E ratio of -12.82 and a beta of 0.94. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company has a 50-day moving average of $47.76 and a 200 day moving average of $47.90.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The firm had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. On average, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on TARS shares. HC Wainwright reiterated a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Guggenheim reiterated a "buy" rating and set a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Barclays cut their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Jefferies Financial Group raised their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Finally, Oppenheimer upped their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $63.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.